Fosamprenavir
- Generic Name
- Fosamprenavir
- Brand Names
- Lexiva, Telzir
- Drug Type
- Small Molecule
- Chemical Formula
- C25H36N3O9PS
- CAS Number
- 226700-79-4
- Unique Ingredient Identifier
- WOU1621EEG
- Background
Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease.
- Indication
Indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection, as well as postexposure prophylaxis of HIV infection in individuals who have had occupational or nonoccupational exposure to potentially infectious body fluids of a person known to be infected with HIV when that exposure represents a substantial risk for HIV transmission. The use of fosamprenavir is pending revision due to a potential association between the drug and myocardial infarction and dyslipidemia in HIV infected adults.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Dual Versus Triple Protease Inhibitor Combinations, Including Ritonavir, in HIV Infected People
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-28
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 56
- Registration Number
- NCT00028366
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-12-05
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 53
- Registration Number
- NCT00027339
- Locations
- 🇺🇸
USC CRS, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
🇺🇸Beth Israel Med. Ctr., ACTU, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.